Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$1.71
$0.01(0.80%)
At close: 4:00 PM EDT
$1.71
$0.01(0.80%)
Day’s Range― - ―
52-Week Range$0.87 - $2.99
Previous Close$1.26
Volume536.26K
Average Volume (3M)1.80M
Market Cap
$132.65M
Enterprise Value$72.05
Total Cash (Recent Filing)$34.82M
Total Debt (Recent Filing)$877.00K
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 03, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding72,483,850
10 Day Avg. Volume1,583,857
30 Day Avg. Volume1,798,103
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.80Price Target Upside297.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage limits fixed financial obligations and gives Biomea greater flexibility while it advances clinical programs. A relatively low debt burden can reduce refinancing pressure and preserve more strategic options than a highly leveraged balance sheet during continued development spending.
Narrowing LossesThe substantial reduction in net losses indicates improving cost control and a lower rate of earnings deterioration. Although Biomea remains unprofitable, continued progress in containing losses could extend financial flexibility and support more disciplined investment in its pipeline.
Proprietary Drug PlatformA proprietary discovery platform provides an internally controlled basis for generating small-molecule candidates across oncology and metabolic disease areas. Its focus on selectively and durably inhibiting disease-driving proteins could support differentiated clinical programs if development results validate the approach.
Bears Say
No Commercial RevenueWithout approved products or recurring customer revenue, Biomea lacks an established operating engine to fund research and development. The absence of commercial sales leaves future financial performance dependent on clinical progress, eventual approvals, and potential partnership economics.
Persistent Cash BurnPersistent negative operating and free cash flow means Biomea must continue spending capital before its pipeline can generate revenue. Even with improved burn versus prior years, ongoing external financing dependence can constrain development choices and create funding risk over the next several quarters.
Shrinking Capital CushionThe sharp decline in equity reflects cumulative losses and leaves a materially thinner capital cushion for a company that is still pre-commercial. Reduced balance-sheet resources may limit the ability to absorb setbacks or fund multiple clinical programs without additional financing.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $2.99 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $132.65M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Nov 03, 2026 which is in 42 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Aug 05, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.103.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.23.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,483,850 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.80 (297.66% Upside)
$6.80 (297.66% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 53.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 145.2%
Last 30 Days ▲ 145.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biomea Fusion
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
BMEA Stock 12 Month Forecast
Average Price Target
$6.80
▲(297.66% Upside)
Technical Analysis
Ownership Overview
3.71% Insiders
11.19% Mutual Funds
4.75% Other Institutional Investors
76.12% Public Companies and
Individual Investors